1-3 of 3
Qingyu Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models

Xiaoping Zhang, Hua Lv, Qingyu Zhou, Rana Elkholi, Jerry E. Chipuk, M.V. Ramana Reddy, E. Premkumar Reddy, James M. Gallo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (5): 1105–1116.
https://doi.org/10.1158/1535-7163.MCT-13-0847
Published: 05 May 2014
View article titled, Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models
Open the PDF for Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models in another window
Journal Articles

Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib

Shining Wang, Qingyu Zhou, James M. Gallo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (6): 1438–1447.
https://doi.org/10.1158/1535-7163.MCT-09-0089
Published: 10 June 2009
View article titled, Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib
Open the PDF for Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib in another window
Includes: Supplementary data
Journal Articles

Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models

Shining Wang, Ping Guo, Xiaomin Wang, Qingyu Zhou, James M. Gallo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (2): 407–417.
https://doi.org/10.1158/1535-7163.MCT-07-2070
Published: 15 February 2008
View article titled, Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Open the PDF for Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models in another window